About Us
Company Overview
Executive Team
Board of Directors
Scientific Advisory Board
Contact
Science & Pipeline
R&D Platform
Pipeline
Publications
Patients
Partners
Business Development
Current Partners
Media
Press Release
Media Report
Careers
Corporate Culture
Job Opportunities
中文
中文
About Us
Company Overview
Executive Team
Board of Directors
Scientific Advisory Board
Contact
Science & Pipeline
R&D Platform
Pipeline
Publications
Patients
Partners
Business Development
Current Partners
Media
Press Release
Media Report
Careers
Corporate Culture
Job Opportunities
Develop Differentiated Innovative Medicines
R&D Platform
Pipeline
AN2025 (buparlisib)
AN0025 (palupiprant)
AN4005
AN3025
AN1025
AN8025
AN6025
Publications
AN2025
28
2018-02
Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1
25
2017-01
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or static squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial
AN0025
17
2020-06
First-in- human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
27
2019-09
A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Rectal Cancer
AN3025
16
2022-02
Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity
AN1004
06
2022-12
A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/static breast cancer (REO 026-1)
13
2017-10
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with static breast cancer: final analysis of Canadian Cancer Trials Group IND.213.